Endocrine Abstracts

Background and aim: Somatostatin analogues such as octreotide acetate were used in acromegalic patients as primary or secondary treatment. In this study we aimed to report completely disappearing of adenoma and clinical cure in 3 acromegalic cases that rejected surgical treatment.

Case1: E.A (62 years old, female) She reported enlargement of his hands, deepening of his voice and increases in shoe size. MRI revealed a macro adenoma which was spread to cavernous sinus (20×15 mm). She has been treated ocreotide-LAR 20 mg/per month for 24 month. Adenoma size gradually became small and completely disappeared after 24 months.

Case 2: S.S (46 years old, male) Magnetic resonance imaging (MRI) revealed a 12 mm pituitary macro adenoma. He has been treated with octreotide-LAR 20 mg/per month for 25 months. After Eight months octreotide LAR treatment adenoma disappeared. Octreotide-LAR treatment was continued because risk of enlargement of adenoma

Case3: B.U (44 years old, male) Magnetic resonance imaging (MRI) revealed a 9 mm pituitary adenoma. He had treated with short acting octreotide analogue for 6 month (octreotide 100 μ three times a day) then he has treated with octreotide-LAR 20–30 mg/month for 36 months. With this treatment pituitary adenoma of the patient completely disappeared in MRI of pituitary gland.

Age and sex matched serum IGF-1 levels decreased to normal range in case 1. IGF-1 levels of case 2 and case 3 decreased but not achieved to normal range. Growth hormone levels of the patients with the treatment achieved normal range in case 2. Growth hormone levels during oral glucose tolerance test decreased in case 1 and case 3 but not achieve normal range. Biochemical data were shown in the table.

Conclusions: 1- Octreotide treatment decreased IGF-1and GH hormone levels in acromegalic patients.

2- Adenomas may completely disappeared with octreotide-LAR treatment

3- Octreotide-LAR treatment may be used in selected patients instead of surgical treatment.